Veru Management
Management criteria checks 3/4
Veru's CEO is Mitch Steiner, appointed in Oct 2016, has a tenure of 7.5 years. total yearly compensation is $4.71M, comprised of 18.4% salary and 81.6% bonuses, including company stock and options. directly owns 5.01% of the company’s shares, worth $9.31M. The average tenure of the management team and the board of directors is 5.6 years and 3.3 years respectively.
Key information
Mitch Steiner
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 18.4% |
| CEO tenure | 7.5yrs |
| CEO ownership | 5.0% |
| Management average tenure | 5.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Jan 09
Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
Aug 16Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Apr 17Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
Feb 14Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Jan 13Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically
Nov 13Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict
Oct 17Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?
Sep 26Veru FDA AdCom meeting for COVID-19 therapy postponed
Sep 19Veru: A Good Combination Of A Stable Business And Growth Opportunities
Sep 13Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy
Sep 07Veru sheds 13% to end rally as director sells shares
Aug 18Veru Q3 2022 Earnings Preview
Aug 10Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Aug 03Veru eligible for expedited review in U.K. for COVID-19 therapy
Jul 25Veru: The Signs Seem To Point To An EUA For Sabizabulin
Jul 13Veru phase 3 results of sabizabulin for COVID-19 published in NEJM
Jul 06Veru: On Right Track For FDA EUA Submission
May 27Is Veru (NASDAQ:VERU) Using Debt Sensibly?
May 25Veru: Where Big Pharma Failed To Tread
May 17Veru: The Russian/Ukraine Conflict May Pose Challenges
Mar 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$63m |
| Sep 30 2023 | US$5m | US$866k | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$125m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | n/a | n/a | -US$116m |
| Sep 30 2022 | US$6m | US$761k | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | n/a | n/a | -US$16m |
| Sep 30 2021 | US$2m | US$618k | US$7m |
| Jun 30 2021 | n/a | n/a | -US$144k |
| Mar 31 2021 | n/a | n/a | -US$476k |
| Dec 31 2020 | n/a | n/a | US$2m |
| Sep 30 2020 | US$1m | US$502k | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$13m |
| Sep 30 2019 | US$800k | US$392k | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | n/a | n/a | -US$22m |
| Sep 30 2018 | US$740k | US$383k | -US$24m |
| Jun 30 2018 | n/a | n/a | -US$21m |
| Mar 31 2018 | n/a | n/a | -US$14m |
| Dec 31 2017 | n/a | n/a | -US$11m |
| Sep 30 2017 | US$831k | US$406k | -US$9m |
Compensation vs Market: Mitch's total compensation ($USD4.71M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.
CEO
Mitch Steiner (62 yo)
7.5yrs
Tenure
US$4,714,041
Compensation
Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.5yrs | US$4.71m | 5.01% $ 9.3m | |
| Vice Chairman & Chief Corporate Officer | 7.5yrs | no data | 5.47% $ 10.2m | |
| CFO & Chief Administrative Officer | 6.3yrs | US$1.55m | 0.066% $ 122.1k | |
| Chief Scientific Officer | 5.6yrs | US$1.69m | 0% $ 0 | |
| Executive Director of Investor Relations & Corporate Communications | 5yrs | no data | no data | |
| Executive VP | 3.1yrs | no data | no data | |
| Executive Vice President of Corporate Development | 7.3yrs | no data | no data | |
| Executive Vice President of FC2 Global Operations | no data | US$193.01k | no data | |
| Executive VP & Deputy General Counsel | 3.3yrs | no data | no data | |
| Executive Vice President of Global Clinical Operations | 6yrs | no data | no data | |
| Executive Vice President of Quality & Regulatory Affairs | 5.2yrs | no data | no data | |
| Executive VP and GM of UK | 1.7yrs | no data | no data |
5.6yrs
Average Tenure
61.5yo
Average Age
Experienced Management: VERU's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.5yrs | US$4.71m | 5.01% $ 9.3m | |
| Vice Chairman & Chief Corporate Officer | 7.5yrs | no data | 5.47% $ 10.2m | |
| Chief Medical Advisor & Member of the Scientific Advisory | less than a year | no data | no data | |
| Chairman of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Board Observer | 7.5yrs | no data | no data | |
| Member of the Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 6.1yrs | US$875.93k | 0.068% $ 127.0k | |
| Independent Director | 2.9yrs | US$835.75k | 0.0067% $ 12.4k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 7.5yrs | US$795.57k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$755.39k | 0.010% $ 18.8k | |
| Member of the Scientific Advisory Board | less than a year | no data | no data |
3.3yrs
Average Tenure
65yo
Average Age
Experienced Board: VERU's board of directors are considered experienced (3.3 years average tenure).